{"id":39414,"date":"2025-08-15T14:51:06","date_gmt":"2025-08-15T06:51:06","guid":{"rendered":"https:\/\/flcube.com\/?p=39414"},"modified":"2025-08-15T14:51:07","modified_gmt":"2025-08-15T06:51:07","slug":"superluminal-collaborates-with-eli-lilly-on-small-molecule-therapeutics-for-cardiometabolic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39414","title":{"rendered":"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases"},"content":{"rendered":"\n

Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY<\/a>) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. This strategic partnership leverages Superluminal’s proprietary platform to discover and optimize compounds for these targets.<\/p>\n\n\n\n

Collaboration Details<\/strong>
Under the agreement, Superluminal will utilize its platform to discover and optimize small-molecule therapeutics for undisclosed GPCR targets associated with cardiometabolic diseases and obesity. Once Superluminal delivers development candidates meeting predefined criteria, Lilly will gain exclusive rights to develop and commercialize these compounds.<\/p>\n\n\n\n

Financial Terms<\/strong>
Superluminal stands to receive up to $1.3 billion under the agreement. This includes upfront and near-term payments, an equity investment, development and commercial milestones, and tiered royalties on net sales. The collaboration underscores Lilly’s commitment to advancing innovative therapeutics in cardiometabolic health.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to…<\/p>\n","protected":false},"author":1,"featured_media":39416,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[69,199,911,4285],"class_list":["post-39414","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cvd","tag-eli-lilly","tag-nyse-lly","tag-superluminal-medicines"],"yoast_head":"\nSuperluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. This strategic partnership leverages Superluminal's proprietary platform to discover and optimize compounds for these targets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39414\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases\" \/>\n<meta property=\"og:description\" content=\"Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. This strategic partnership leverages Superluminal's proprietary platform to discover and optimize compounds for these targets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39414\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T06:51:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-15T06:51:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases\",\"datePublished\":\"2025-08-15T06:51:06+00:00\",\"dateModified\":\"2025-08-15T06:51:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414\"},\"wordCount\":148,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1510.webp\",\"keywords\":[\"CVD\",\"Eli Lilly\",\"NYSE: LLY\",\"Superluminal Medicines\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39414#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39414\",\"name\":\"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1510.webp\",\"datePublished\":\"2025-08-15T06:51:06+00:00\",\"dateModified\":\"2025-08-15T06:51:07+00:00\",\"description\":\"Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. This strategic partnership leverages Superluminal's proprietary platform to discover and optimize compounds for these targets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39414\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1510.webp\",\"width\":1080,\"height\":608,\"caption\":\"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39414#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases - Insight, China's Pharmaceutical Industry","description":"Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. This strategic partnership leverages Superluminal's proprietary platform to discover and optimize compounds for these targets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39414","og_locale":"en_US","og_type":"article","og_title":"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases","og_description":"Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. This strategic partnership leverages Superluminal's proprietary platform to discover and optimize compounds for these targets.","og_url":"https:\/\/flcube.com\/?p=39414","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-15T06:51:06+00:00","article_modified_time":"2025-08-15T06:51:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39414#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39414"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases","datePublished":"2025-08-15T06:51:06+00:00","dateModified":"2025-08-15T06:51:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39414"},"wordCount":148,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39414#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1510.webp","keywords":["CVD","Eli Lilly","NYSE: LLY","Superluminal Medicines"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39414#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39414","url":"https:\/\/flcube.com\/?p=39414","name":"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39414#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39414#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1510.webp","datePublished":"2025-08-15T06:51:06+00:00","dateModified":"2025-08-15T06:51:07+00:00","description":"Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. This strategic partnership leverages Superluminal's proprietary platform to discover and optimize compounds for these targets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39414#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39414"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39414#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1510.webp","width":1080,"height":608,"caption":"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39414#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39414"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39414\/revisions"}],"predecessor-version":[{"id":39417,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39414\/revisions\/39417"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39416"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}